全文获取类型
收费全文 | 1272900篇 |
免费 | 94169篇 |
国内免费 | 1975篇 |
专业分类
耳鼻咽喉 | 18180篇 |
儿科学 | 42237篇 |
妇产科学 | 37805篇 |
基础医学 | 186673篇 |
口腔科学 | 35334篇 |
临床医学 | 107795篇 |
内科学 | 250505篇 |
皮肤病学 | 26465篇 |
神经病学 | 99172篇 |
特种医学 | 49982篇 |
外国民族医学 | 366篇 |
外科学 | 197359篇 |
综合类 | 26492篇 |
现状与发展 | 1篇 |
一般理论 | 300篇 |
预防医学 | 92299篇 |
眼科学 | 28987篇 |
药学 | 97737篇 |
1篇 | |
中国医学 | 2495篇 |
肿瘤学 | 68859篇 |
出版年
2018年 | 11810篇 |
2015年 | 11616篇 |
2014年 | 16005篇 |
2013年 | 24357篇 |
2012年 | 33573篇 |
2011年 | 35963篇 |
2010年 | 21220篇 |
2009年 | 20029篇 |
2008年 | 35006篇 |
2007年 | 37975篇 |
2006年 | 38539篇 |
2005年 | 37827篇 |
2004年 | 36422篇 |
2003年 | 35392篇 |
2002年 | 34937篇 |
2001年 | 58120篇 |
2000年 | 59604篇 |
1999年 | 50703篇 |
1998年 | 14243篇 |
1997年 | 12813篇 |
1996年 | 13075篇 |
1995年 | 12353篇 |
1994年 | 11761篇 |
1993年 | 10863篇 |
1992年 | 40995篇 |
1991年 | 40366篇 |
1990年 | 39869篇 |
1989年 | 38687篇 |
1988年 | 36087篇 |
1987年 | 35327篇 |
1986年 | 33699篇 |
1985年 | 32124篇 |
1984年 | 23898篇 |
1983年 | 20782篇 |
1982年 | 12324篇 |
1981年 | 10878篇 |
1980年 | 10151篇 |
1979年 | 22604篇 |
1978年 | 15837篇 |
1977年 | 13684篇 |
1976年 | 12932篇 |
1975年 | 14165篇 |
1974年 | 16661篇 |
1973年 | 16042篇 |
1972年 | 15308篇 |
1971年 | 14222篇 |
1970年 | 13203篇 |
1969年 | 12723篇 |
1968年 | 11969篇 |
1967年 | 10458篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
121.
Clinical Spectrum of Capillary Malformation–Arteriovenous Malformation Syndrome Presenting to a Pediatric Dermatology Practice: A Retrospective Study 下载免费PDF全文
Nicole A. Weitz M.D. Christine T. Lauren M.D. Gerald G. Behr M.D. June K. Wu M.D. Jessica J. Kandel M.D. Philip M. Meyers M.D. Sally Sultan M.D. Kwame Anyane‐Yeboa M.D. Kimberly D. Morel M.D. Maria C. Garzon M.D. 《Pediatric dermatology》2015,32(1):76-84
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature. 相似文献
122.
123.
124.
125.
Mohamad Abbass Brendan G. Santyr Andrew G. Parrent Keith W. MacDougall Michael D. Staudt 《Neuromodulation》2020,23(6):831-837
ObjectiveStimulation of the dorsal spinal roots, or spinal nerve root stimulation (SNRS), is a neuromodulation modality that can target pain within specific dermatomal distributions. The use of paresthesia-free stimulation has been described with conventional dorsal column spinal cord stimulation, although has yet to be described for SNRS. This objective of this study was to investigate the efficacy of paresthesia-free high-frequency (1000–1200 Hz) SNRS in the treatment of intractable, dermatomal neuropathic pain.Materials and MethodsA retrospective chart review was performed on 14 patients implanted with SNRS in varying distributions: Ten patients initially received tonic stimulation and crossed over to a paresthesia-free paradigm and four patients received only paresthesia-free stimulation. The primary outcome was reduction in pain severity (visual analog scale [VAS]), measured at baseline and follow-up to 24 months with paresthesia-free stimulation.ResultsAll 14 patients who received paresthesia-free stimulation had significant improvement in pain severity at a mean follow-up of 1.39 ± 0.15 years (VAS 7.46 at baseline vs. 3.25 at most recent follow-up, p < 0.001). Ten patients were initially treated with tonic stimulation and crossed over to paresthesia-free stimulation after a mean of 61.7 months. Baseline pain in these crossover patients was significantly improved at last follow-up with tonic stimulation (VAS 7.65 at baseline vs. 2.83 at 48 months, p < 0.001), although all patients developed uncomfortable paresthesias. There was no significant difference in pain severity between patients receiving tonic and paresthesia-free stimulation.ConclusionsWe present real-world outcomes of patients with intractable dermatomal neuropathic pain treated with paresthesia-free, high-frequency SNRS. We demonstrate its effectiveness in providing pain reduction at a level comparable to tonic SNRS up to 24 months follow-up, without producing uncomfortable paresthesias. 相似文献
126.
Phonphimon Wongthida Matthew R Schuelke Christopher B Driscoll Timothy Kottke Jill M Thompson Jason Tonne Cathy Stone Amanda L Huff Cynthia Wetmore James A Davies Alan L Parker Laura Evgin Richard G Vile 《Neuro-oncology》2020,22(12):1757
BackgroundDiffuse midline glioma, formerly DIPG (diffuse intrinsic pontine glioma), is the deadliest pediatric brainstem tumor with median survival of less than one year. Here, we investigated (i) whether direct delivery of adenovirus-expressing cluster of differentiation (CD)40 ligand (Ad-CD40L) to brainstem tumors would induce immune-mediated tumor clearance and (ii) if so, whether therapy would be associated with a manageable toxicity due to immune-mediated inflammation in the brainstem.MethodsSyngeneic gliomas in the brainstems of immunocompetent mice were treated with Ad-CD40L and survival, toxicity, and immune profiles determined. A clinically translatable vector, whose replication would be tightly restricted to tumor cells, rAd-Δ24-CD40L, was tested in human patient–derived diffuse midline gliomas and immunocompetent models.ResultsExpression of Ad-CD40L restricted to brainstem gliomas by pre-infection induced complete rejection, associated with immune cell infiltration, of which CD4+ T cells were critical for therapy. Direct intratumoral injection of Ad-CD40L into established brainstem tumors improved survival and induced some complete cures but with some acute toxicity. RNA-sequencing analysis showed that Ad-CD40L therapy induced neuroinflammatory immune responses associated with interleukin (IL)-6, IL-1β, and tumor necrosis factor α. Therefore, to generate a vector whose replication, and transgene expression, would be tightly restricted to tumor cells, we constructed rAd-Δ24-CD40L, the backbone of which has already entered clinical trials for diffuse midline gliomas. Direct intratumoral injection of rAd-Δ24-CD40L, with systemic blockade of IL-6 and IL-1β, generated significant numbers of cures with readily manageable toxicity.ConclusionsVirus-mediated delivery of CD40L has the potential to be effective in treating diffuse midline gliomas without obligatory neuroinflammation-associated toxicity. 相似文献
127.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.128.
129.
130.
Jünemann A. G. M. Rejdak R. Hohberger B. 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》2016,113(11):897-905
Die Ophthalmologie - Die Filtrationsverfahren sind im Gegensatz zu allen anderen Glaukomoperationen mit einer biomikroskopisch sichtbaren Wundheilung assoziiert, sodass eine Vielzahl von... 相似文献